{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:54Z","timestamp":1740107094535,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Brain Res"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00221-022-06390-y","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:03:06Z","timestamp":1655204586000},"page":"1933-1941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous dopaminergic stimulation counteracts l-DOPA-induced overactivity of Ca2+ in 6-OHDA-lesioned rats"],"prefix":"10.1007","volume":"240","author":[{"given":"Jie","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fugang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-0715","authenticated-orcid":false,"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"6390_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/0960327118806633","volume":"38","author":"M Ba","year":"2019","unstructured":"Ba M, Ding W, Guan L, Lv Y, Kong M (2019) S-Nitrosylation of Src by NR2B-nNOS signal causes Src activation and NR2B tyrosine phosphorylation in levodopa-induced dyskinetic rat model. Hum Exp Toxicol 38:303\u2013310. https:\/\/doi.org\/10.1177\/0960327118806633","journal-title":"Hum Exp Toxicol"},{"key":"6390_CR2","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","volume":"14","author":"F Blandini","year":"2008","unstructured":"Blandini F, Armentero M-T, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14:S124\u2013S129","journal-title":"Parkinsonism Relat Disord"},{"key":"6390_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/WNF.0B013E3181761466","volume":"32","author":"F Blandini","year":"2009","unstructured":"Blandini F, Bazzini E, Marino F, Saporiti F, Armentero MT, Pacchetti C, Zangaglia R, Martignoni E, Lecchini S, Nappi G, Cosentino M (2009) Calcium homeostasis is dysregulated in parkinsonian patients with l-DOPA-induced dyskinesias. Clin Neuropharmacol 32:133\u2013139. https:\/\/doi.org\/10.1097\/WNF.0B013E3181761466","journal-title":"Clin Neuropharmacol"},{"key":"6390_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0028-3843(14)60298-x","volume":"44","author":"A Bogucki","year":"2010","unstructured":"Bogucki A, S\u0142awek J (2010) Ci\u0105g\u0142a stymulacja dopaminergiczna\u2014do\u015bwiadczenia kliniczne. Neurol Neurochir Pol 44:385\u2013395. https:\/\/doi.org\/10.1016\/s0028-3843(14)60298-x","journal-title":"Neurol Neurochir Pol"},{"key":"6390_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nbd.2012.10.013","volume":"50","author":"LS Breger","year":"2013","unstructured":"Breger LS, Dunnett SB, Lane EL (2013) Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiol Dis 50:142\u2013150","journal-title":"Neurobiol Dis"},{"key":"6390_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-12-381328-2.00005-5","volume":"98","author":"J Brotchie","year":"2011","unstructured":"Brotchie J, Jenner P (2011) New approaches to therapy. Int Rev Neurobiol 98:123\u2013150. https:\/\/doi.org\/10.1016\/B978-0-12-381328-2.00005-5","journal-title":"Int Rev Neurobiol"},{"key":"6390_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-04609-4","volume-title":"Immunohistochemistry: Basics and Methods","author":"IB Buchwalow","year":"2010","unstructured":"Buchwalow IB, B\u00f6cker W (2010) Background staining, autofluorescence and blocking steps. Immunohistochemistry: Basics and methods. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-04609-4_5"},{"key":"6390_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/mds.27959","volume":"35","author":"MA Cenci","year":"2020","unstructured":"Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA (2020) Dyskinesia matters. Mov Disord 35:392\u2013396. https:\/\/doi.org\/10.1002\/mds.27959","journal-title":"Mov Disord"},{"key":"6390_CR9","doi-asserted-by":"publisher","first-page":"6.2.1","DOI":"10.1002\/0471143030.cb0602s52","volume":"52","author":"S Gallagher","year":"2011","unstructured":"Gallagher S, Winston SE, Fuller SA, Hurrell JG (2011) Immunoblotting and immunodetection. Curr Protoc Cell Biol 52:6.2.1-6.2.28","journal-title":"Curr Protoc Cell Biol"},{"key":"6390_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ana.22423","volume":"69","author":"MD Gottwald","year":"2011","unstructured":"Gottwald MD, Aminoff MJ (2011) Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 69:919\u2013927. https:\/\/doi.org\/10.1002\/ana.22423","journal-title":"Ann Neurol"},{"key":"6390_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-3-7091-8954-2_21","volume":"27","author":"R Horowski","year":"1988","unstructured":"Horowski R, Marsden CD, Obeso JA (1988) Continuous dopaminergic stimulation: state of the art and outlook. J Neural Transm Suppl 27:249\u2013252. https:\/\/doi.org\/10.1007\/978-3-7091-8954-2_21","journal-title":"J Neural Transm Suppl"},{"key":"6390_CR12","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1212\/wnl.62.1_suppl_1.s47","volume":"62","author":"P Jenner","year":"2004","unstructured":"Jenner P (2004) Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62:S47\u2013S55. https:\/\/doi.org\/10.1212\/wnl.62.1_suppl_1.s47","journal-title":"Neurology"},{"key":"6390_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12640-019-00109-8","volume":"37","author":"NCF Junior","year":"2020","unstructured":"Junior NCF, Dos-Santos-Pereira M, Guimaraes FS, Del Bel E (2020) Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson\u2019s Disease and l-DOPA-induced dyskinesia. Neurotox Res 37:12\u201329. https:\/\/doi.org\/10.1007\/s12640-019-00109-8","journal-title":"Neurotox Res"},{"key":"6390_CR14","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1111\/bph.14663","volume":"176","author":"E Keifman","year":"2019","unstructured":"Keifman E, Ruiz-DeDiego I, Pafundo DE, Paz RM, Solis O, Murer MG, Moratalla R (2019) Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after l-DOPA in a mouse model of Parkinson\u2019s disease. Br J Pharmacol 176:2146\u20132161. https:\/\/doi.org\/10.1111\/bph.14663","journal-title":"Br J Pharmacol"},{"key":"6390_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.expneurol.2013.01.019","volume":"247","author":"C Kobylecki","year":"2013","unstructured":"Kobylecki C, Crossman AR, Ravenscroft P (2013) Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease and l-DOPA-induced dyskinesia. Exp Neurol 247:476\u2013484. https:\/\/doi.org\/10.1016\/j.expneurol.2013.01.019","journal-title":"Exp Neurol"},{"key":"6390_CR16","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s40265-019-01170-5","volume":"79","author":"T Muller","year":"2019","unstructured":"Muller T, Mohr JD (2019) Recent clinical advances in pharmacotherapy for levodopa-induced dyskinesia. Drugs 79:1367\u20131374. https:\/\/doi.org\/10.1007\/s40265-019-01170-5","journal-title":"Drugs"},{"key":"6390_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol 2:382\u2013392. https:\/\/doi.org\/10.1038\/ncpneuro0222","journal-title":"Nat Clin Pract Neurol"},{"key":"6390_CR18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Calabresi P, Obeso JA (2020) Continuous dopaminergic stimulation as a treatment for Parkinson\u2019s disease: current status and future opportunities. Mov Disord 35:1731\u20131744. https:\/\/doi.org\/10.1002\/mds.28215","journal-title":"Mov Disord"},{"key":"6390_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.neuro.2005.02.002","volume":"26","author":"B Picconi","year":"2005","unstructured":"Picconi B, Pisani A, Barone I, Bonsi P, Centonze D, Bernardi G, Calabresi P (2005) Pathological synaptic plasticity in the striatum: implications for Parkinson\u2019s disease. Neurotoxicology 26:779\u2013783","journal-title":"Neurotoxicology"},{"key":"6390_CR20","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1097\/NRL.0b013e31823966e3","volume":"17","author":"MC Rodriguez-Oroz","year":"2011","unstructured":"Rodriguez-Oroz MC, Marin C, de Fabregues O (2011) Continuous dopaminergic stimulation: clinical aspects and experimental bases. Neurologist 17:S30\u2013S37. https:\/\/doi.org\/10.1097\/NRL.0b013e31823966e3","journal-title":"Neurologist"},{"key":"6390_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpba.2017.07.018","volume":"146","author":"C Sha","year":"2017","unstructured":"Sha C, Han J, Zhao F, Shao X, Yang H, Wang L, Yu F, Liu W, Li Y (2017) Validated LC-MS\/MS method for the simultaneous determination of rotigotine and its prodrug in rat plasma and an application to pharmacokinetics and biological conversion in vitro. J Pharm Biomed Anal 146:24\u201328. https:\/\/doi.org\/10.1016\/j.jpba.2017.07.018","journal-title":"J Pharm Biomed Anal"},{"key":"6390_CR22","doi-asserted-by":"publisher","first-page":"S316","DOI":"10.1007\/s00415-011-6024-y","volume":"258","author":"F Stocchi","year":"2011","unstructured":"Stocchi F (2011) Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J Neurol 258:S316\u2013S322. https:\/\/doi.org\/10.1007\/s00415-011-6024-y","journal-title":"J Neurol"},{"key":"6390_CR23","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-181476","volume":"8","author":"DJ van Wamelen","year":"2018","unstructured":"van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P (2018) Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson\u2019s disease. J Parkinsons Dis 8:S65\u2013S72. https:\/\/doi.org\/10.3233\/JPD-181476","journal-title":"J Parkinsons Dis"},{"key":"6390_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.biopha.2018.08.062","volume":"107","author":"XS Wang","year":"2018","unstructured":"Wang XS, Zhang ZR, Zhang XR, Chen SY, Shao B, Xie CL (2018) Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson\u2019s rats. Biomed Pharmacother 107:769\u2013776. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.062","journal-title":"Biomed Pharmacother"},{"key":"6390_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1091\/mbc.e12-12-0863","volume":"25","author":"M Winey","year":"2014","unstructured":"Winey M, Meehl JB, O\u2019Toole ET, Giddings TH Jr (2014) Conventional transmission electron microscopy. Mol Biol Cell 25:319\u2013323","journal-title":"Mol Biol Cell"},{"key":"6390_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.brainres.2018.02.013","volume":"1687","author":"X Yang","year":"2018","unstructured":"Yang X, Zhu Z, Ding X, Wang X, Cui G, Hua F, Xiang J (2018) CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson\u2019s disease. Brain Res 1687:66\u201373. https:\/\/doi.org\/10.1016\/j.brainres.2018.02.013","journal-title":"Brain Res"},{"key":"6390_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3389\/fnins.2020.00785","volume":"14","author":"SJ Yu","year":"2020","unstructured":"Yu SJ, Chen S, Yang YY, Glotfelty EJ, Jung J, Kim HK, Choi HI, Choi DS, Hoffer BJ, Greig NH, Wang Y (2020) PT320, sustained-release exendin-4, mitigates L-DOPA-induced dyskinesia in a rat 6-hydroxydopamine model of Parkinson\u2019s disease. Front Neurosci 14:785. https:\/\/doi.org\/10.3389\/fnins.2020.00785","journal-title":"Front Neurosci"}],"container-title":["Experimental Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-022-06390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00221-022-06390-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-022-06390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T14:03:48Z","timestamp":1657980228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00221-022-06390-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":27,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6390"],"URL":"https:\/\/doi.org\/10.1007\/s00221-022-06390-y","relation":{},"ISSN":["0014-4819","1432-1106"],"issn-type":[{"type":"print","value":"0014-4819"},{"type":"electronic","value":"1432-1106"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was obtained from the Care and Use of Experimental Animal Research Committee at Yantai University (approval number: YT-YX-2019\u20130097).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}